Abstract
As knowledge of the pathogenesis of psoriasis deepened, the crucial importance of interleukin 23 (IL-23) was recognized. This was also reflected by the development of new therapies.
Guselkumab is the first approved biologic drug with specific inhibition of IL-23. Our article summarizes the therapeutic potential of this drug and recapitulates the latest information on the effect of interleukin 23.